



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Date: April 29, 2026

To
The General Manager,
Department of Corporate Services,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001.

Scrip Code: 524816

Dear Sir/Madam,

Report on Complaints in terms of Part I(A)(6) of the SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 as amended from time to time ("SEBI Master Circular")

Sub: Application under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("LODR Regulations") for the proposed Scheme of Arrangement between Natco Pharma Limited ("Demerged Company") and Natco Crop Health Sciences Limited ("Resulting Company") and their respective Shareholders and Creditors ("Scheme")

This is in reference to the Scheme filed by the Company under Regulation 37 of the LODR Regulations with BSE Limited on March 31, 2026.

As per Part I(A)(6) of the SEBI Master Circular, the Company is, inter-alia, required to submit a 'Report on Complaints' containing the details of complaints received by the Company on the Scheme from various sources within 7 days of expiry of 21 days from the date of uploading of the draft Scheme and related documents on the website of the relevant stock exchange.

The period of 21 days from the date of uploading of the draft Scheme along with related documents by BSE Limited on its website i.e., April 6, 2026 has expired on April 26, 2026. Accordingly, we attach herewith a 'Report on Complaints', as **Annexure - I** to this letter.

The Report on Complaints is also being uploaded on the website of the Company, i.e., <https://files.natcopharma.co.in/investor-relations/scheme-of-arrangement/> as per requirement of the aforementioned said SEBI Master Circular.

We request you to take the above on record as compliance under the applicable provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 and SEBI Circulars.

For Natco Pharma Limited

Chekuri Venkat Ramesh
Company Secretary &
Compliance Officer

Date: April 29, 2026



Annexure - I

Complaints Report

Period of Complaints Report: April 6, 2026 to April 26, 2026

Part A

Sr. No.	Particulars	Number
1.	Number of complaints received directly	Nil
2.	Number of complaints forwarded by Stock Exchange/ SEBI	Nil
3.	Total Number of complaints/comments received (1+2)	Nil
4.	Number of complaints resolved	Not Applicable
5.	Number of complaints pending	Not Applicable

Part B

Sr. No.	Name of complainant	Date of complaint	Status (Resolved/Pending)
1.	Not Applicable		

For Natco Pharma Limited

Chekuri Venkat Ramesh
Company Secretary &
Compliance Officer

Date: April 29, 2026